Key Points
- Snehal Patel, CEO of Greenwich LifeSciences, purchased 4,300 shares on Dec. 31 at an average price of $21.36 for $91,848, bringing his direct ownership to 5,599,402 shares valued at about $119.6 million (a 0.08% increase).
- Patel has made multiple recent buys (including 2,900 shares on Dec. 30 and purchases in October–November totaling tens of thousands of shares), indicating ongoing insider accumulation.
- GLSI traded up ~8.9%, has a market cap of roughly $293.8 million, and sees mixed analyst views—an average rating of "Hold" with a consensus price target of $47.50 and notable upside from HC Wainwright (PO $50).
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,300 shares of the stock in a transaction on Wednesday, December 31st. The stock was bought at an average price of $21.36 per share, with a total value of $91,848.00. Following the completion of the acquisition, the chief executive officer directly owned 5,599,402 shares of the company's stock, valued at $119,603,226.72. This trade represents a 0.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Snehal Patel also recently made the following trade(s):
- On Tuesday, December 30th, Snehal Patel bought 2,900 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $21.73 per share, for a total transaction of $63,017.00.
- On Thursday, December 18th, Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $12.62 per share, with a total value of $51,742.00.
- On Tuesday, November 25th, Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $8.37 per share, with a total value of $38,502.00.
- On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $8.43 per share, for a total transaction of $89,358.00.
- On Friday, October 31st, Snehal Patel purchased 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $9.26 per share, for a total transaction of $21,298.00.
Greenwich LifeSciences Trading Up 8.9%
GLSI opened at $21.21 on Tuesday. The company has a market cap of $293.76 million, a price-to-earnings ratio of -14.53 and a beta of 1.47. The stock has a fifty day simple moving average of $11.33 and a two-hundred day simple moving average of $11.04. Greenwich LifeSciences, Inc. has a 12-month low of $7.78 and a 12-month high of $30.82.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.30). On average, analysts predict that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in GLSI. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Greenwich LifeSciences during the second quarter valued at approximately $25,000. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after purchasing an additional 3,168 shares in the last quarter. Strs Ohio purchased a new position in shares of Greenwich LifeSciences in the first quarter worth $177,000. Finally, Citadel Advisors LLC lifted its holdings in shares of Greenwich LifeSciences by 52.1% during the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company's stock valued at $208,000 after purchasing an additional 7,174 shares in the last quarter. Institutional investors own 4.16% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on GLSI. Weiss Ratings reiterated a "sell (d-)" rating on shares of Greenwich LifeSciences in a report on Monday, December 29th. Wall Street Zen upgraded Greenwich LifeSciences from a "sell" rating to a "hold" rating in a research note on Saturday, December 27th. Finally, HC Wainwright lifted their price objective on Greenwich LifeSciences from $39.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, December 30th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $47.50.
Get Our Latest Research Report on GLSI
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
